Biliary tract cancer
Conditions
Interventions
Trial group:GEMOX+Tripleitriumab
Sponsors
Shanghai Cancer Center affiliated to Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged >= 18 years and = 90 g / L (no blood transfusion within 14 days); Neutrophil count >= 1.5 x 10^9 / L; Platelet count >= 80 x 10^9 / L; (2) Biochemical examination: Total bilirubin = 50 ml / min (Cockcroft Gault formula); 6. Patients who sign informed consent voluntarily; 7. Patients with good compliance, their families are willing to cooperate with survival follow-up. *According to AJCC Cancer staging eighth edition
Exclusion criteria
Exclusion criteria: 1. Patients with other incurable malignant tumors at the same time; 2. Pregnant or lactating women should withdraw from the clinical trial if they are pregnant during the study period; 3. Patients who have participated in clinical trials of other drugs within one month; 4. Patients with known history of other systemic diseases before screening; 5. Patients with long-term unhealed wound or incomplete fracture; 6. Patients with a history of organ transplantation; 7. Patients with abnormal coagulation function (PT > 16S, APTT > 43S, TT > 21s, Patients with bleeding tendency (14 days before randomization: INR was within the normal range without anticoagulants); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogues; patients allowed to use low-dose warfarin (1 The dosage of aspirin was less than 100 mg per day; 8. Those patients who had arteriovenous thrombotic events in the previous year, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, were screened; 9. Patients with a history of psychotropic drug abuse and unable to give up or have mental disorders; 10. Patients with a history of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or organ transplantation history; 11. According to the judgment of the researcher, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| conversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;disease control rate;safty; | — |
Countries
China
Contacts
Public ContactLu Wang
Shanghai Cancer Center affiliated to Fudan University
Outcome results
None listed